Genmab is a Danish biotechnology company specializing in antibody-based cancer therapies. It co-created the multiple myeloma medicine daratumumab (Darzalex) with Johnson & Johnson and builds additional oncology assets on proprietary platforms such as DuoBody bispecific antibodies. Revenue and growth depend heavily on partnered commercial products and a pipeline of wholly owned and co-developed antibody candidates for hematologic and solid tumors.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 925 | — | 336 | — |
| Q3 2025 | 1,022 | — | 401 | — |
| Q4 2025 | 1,058 | — | 31 | — |
| Q1 2026 | 896 | — | 53 | — |
| Q2 2026 | 1,155 | 24.9% | 303 | -9.8% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Hesai Group (HSAI), MACOM Technology Solutions Holdings, Inc. (MTSI), SBA Communications Corporation (SBAC), Woodward, Inc. (WWD), Joint Stock Company Kaspi.kz (KSPI), FTAI Aviation Ltd. (FTAI)